可手术切除食管癌综合治疗进展  

Progress in multidisciplinary treatment of resectable esophageal cancer

作　　者：李绪渊(综述)[1] 李蔚冰(综述)[1] 林英城(审校)[1] 

机构地区：[1]汕头大学医学院附属肿瘤医院内科,515031

出　　处：《国际肿瘤学杂志》2010年第8期600-603,共4页Journal of International Oncology

摘　　要：最近几年食管癌治疗方式可选择性逐渐增加，手术仍是早期食管癌主要治疗手段，术前新辅助治疗、术后辅助治疗已逐渐成为可手术食管癌综合治疗的重要组成部分。根治性同期化放疗有可能代替单纯手术作为可手术食管癌治疗的选择。顺铂联合氟尿嘧啶仍是可手术食管癌手术前后辅助治疗的基本方案；新的细胞毒药物如紫杉醇类、拓扑异构酶抑制剂及新联合方案是围手术期治疗研究的热点。In recent years, there has been a gradual increase in treatment options for patients with esophageal cancer. While surgery remains to be the primary treatment, neoadjuvant and adjuvant therapy, both preoperatively and postoperatively, have become more important in the multidisciplinary treatment of resectable esophageal cancer. Definitive concomitant cbemo-radiotherapy may replace surgery as the primary treatment for resectable esophageal cancer. Cisplatin combined with 5-fluorouracil remains the backbone regimen for neoadjuvant and adjuvant therapy. Intense researches arc underway to investigate new cytotoxic drugs such as taxanes and topoisomerase inhibitor, and new regimens ior perioperative treatment of resectable esophageal cancer.

关 键 词：食管肿瘤 综合疗法 新辅助治疗 

分 类 号：R735.1[医药卫生—肿瘤]